Vecuronium Bromide for Injection Rx
Generic Name and Formulations:
Vecuronium bromide 10mg/10mL; pwd for IV inj after reconstitution; contains benzyl alcohol, mannitol.
Various generic manufacturers
Indications for Vecuronium Bromide for Injection:
Adjunct to general anesthesia to facilitate endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Adults and Children:
<7wks: not recommended. Individualize. >7wks–10yrs: see literature. ≥10yrs: Relaxation for intubation: inject bolus dose of 0.08–0.1mg/kg; may reduce dose to 0.06–0.085mg/kg if given >5 minutes after start of inhalation agent or when steady state has been achieved. Give 1microgram/kg/min (range: 0.8–1.2microgram/kg/min) by continuous IV infusion 20–40 minutes after initial dose. Inhalation anesthetics (eg, enflurane, isoflurane): reduce infusion rate 25–60%, 45–60 minutes after initial dose. Intubation with succinylcholine: reduce initial vecuronium dose to 0.04–0.06mg/kg with inhalation anesthesia; and to 0.05–0.06mg/kg with balanced anesthesia. Prolonged surgery: maintenance dose of 0.01–0.015mg/kg, within 25–40 minutes of initial dose. During surgery under halothane anesthesia: initial dosing range from 0.15mg/kg up to 0.28mg/kg have been given. Monitor with a peripheral nerve stimulator to avoid overdosage.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome (do test dose and monitor). Renal failure. Hepatic impairment. Cardiovascular disease and edematous state. Long-term use in I.C.U. Immobilized for long periods. Severe obesity or neuromuscular disease; monitor airway and ventilation. Electrolyte imbalance. Adrenal cortical insufficiency. Malignant hyperthermia. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Neuromuscular blocker (nondepolarizing).
Prior administration of succinylcholine may potentiate effects (delay vecuronium dose). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate, magnesium salts. Additive effects with pancuronium, d-tubocurarine, metocurine, and gallamine. Caution with quinidine injection.
Skeletal muscle weakness or prolonged paralysis, muscle atrophy, respiration insufficiency, apnea; rare: hypersensitivity reactions.
Formerly known under the brand name Norcuron.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Cochrane Data Release and the Case for "Open Science"
- Rate of Type 2 Diabetes in Chronic Kidney Disease
- Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities
- Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D
- Shift Seen From EDs to Urgent Care for Low-Acuity, Acute Care